Organisation paid for research Program year 2023 Source: CMS Open Payments

Virginia Research Center

Neither a doctor nor a teaching hospital

Research payments

$382,524

195 payments

Through program year 2023, Virginia Research Center is reported as receiving $382,524 in research payments, across 195 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $57,147 27
2022 Research $33,403 24
2021 Research $56,909 11
2020 Research $84,351 48
2019 Research $150,714 85

Breakdown

Who paid Research payments · program years 2019–2023
  1. Novo Nordisk AS $261,528 165 payments
  2. Novartis Pharmaceuticals Corporation $109,403 8 payments
  3. Pfizer Inc. $11,593 22 payments
Studies the money was for Research payments · program years 2019–2023
  1. Ex9536-4388 $160,687 155 payments
  2. Nn1250-4252 $97,212 8 payments
  3. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $60,571 4 payments
  4. A 24 Week Multicenter Double Blind Placebo Controlled Dose Ranging Study to Investigate the Efficacy and Safety of Oral Qbw251 in COPD Patients on Triple Therapy (Laba/Lama/Ics) $48,832 4 payments
  5. A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $6,784 1 payment
  6. Nn9068-4228 $3,629 2 payments
  7. A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $3,241 6 payments
  8. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $864 12 payments
  9. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $404 1 payment
  10. A Phase 3 Randomized Doubleblind Placebocontrolled 26Week Multicenter Study With A 78Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Mo $160 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record